250 related articles for article (PubMed ID: 30030359)
1. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
Ma J; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
[TBL] [Abstract][Full Text] [Related]
2. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
3. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
4. Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.
Rosenberg AS; Cherney B; Brorson K; Clouse K; Kozlowski S; Hughes P; Friedman R
PDA J Pharm Sci Technol; 2011; 65(6):563-7. PubMed ID: 22294578
[TBL] [Abstract][Full Text] [Related]
5. Proceedings of the 2017 Viral Clearance Symposium, Session 6: Ensuring Viral Safety in Continuous Processing.
Johnson SA; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):516-524. PubMed ID: 30030352
[TBL] [Abstract][Full Text] [Related]
6. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
Kreil TR; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
[TBL] [Abstract][Full Text] [Related]
7. Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies.
Schwantes A; Specht R; Chen Q
PDA J Pharm Sci Technol; 2018; 72(5):498-510. PubMed ID: 30030357
[TBL] [Abstract][Full Text] [Related]
8. Proceedings of the 2017 Viral Clearance Symposium, Session 1.2: Upstream Mitigation, Part 2-Virus Barrier Filter and HTST.
Chen D; Bolton G
PDA J Pharm Sci Technol; 2018; 72(5):462-469. PubMed ID: 30030355
[TBL] [Abstract][Full Text] [Related]
9. Proceedings of the 2017 Viral Clearance Symposium: Conclusion.
Hepbildikler S; Johnson S; Bluemel J
PDA J Pharm Sci Technol; 2018; 72(5):525-530. PubMed ID: 30030353
[TBL] [Abstract][Full Text] [Related]
10. Determining the Clearance of Degraded Protein via a Monoclonal Antibody Purification Process in Support of Cleaning Carryover Limits in Multiproduct Facilities.
Che PL; Bailey AP; Tam CYJ; Alvarez M; Arroyo AY
PDA J Pharm Sci Technol; 2020; 74(4):377-393. PubMed ID: 32179711
[TBL] [Abstract][Full Text] [Related]
11. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
12. Proceedings of the 2019 Viral Clearance Symposium, Session 7: Cell Banks and U.S. Pharmacopeia.
O'Donnell S
PDA J Pharm Sci Technol; 2022; 76(4):358-361. PubMed ID: 34911823
[TBL] [Abstract][Full Text] [Related]
13. Proceedings of the 2009 Viral Clearance Symposium.
Miesegaes G; Bailey M; Willkommen H; Chen Q; Roush D; Blümel J; Brorson K
Dev Biol (Basel); 2010; 133():3-101. PubMed ID: 21516942
[TBL] [Abstract][Full Text] [Related]
14. Proceedings of the 2017 Viral Clearance Symposium.
Hepbildikler S; Nothelfer F
PDA J Pharm Sci Technol; 2018; 72(5):453-454. PubMed ID: 30030350
[TBL] [Abstract][Full Text] [Related]
15. Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.
Roush D; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):479-487. PubMed ID: 30030354
[TBL] [Abstract][Full Text] [Related]
16. Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice--validation of virus removal and inactivation.
Trijzelaar B
Biotherapy; 1993; 6(2):93-102. PubMed ID: 8398576
[TBL] [Abstract][Full Text] [Related]
17. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
Ma J
PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
[TBL] [Abstract][Full Text] [Related]
18. Proceedings of the 2019 Viral Clearance Symposium, Session 8. Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments and Actions.
Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):362-367. PubMed ID: 34911826
[TBL] [Abstract][Full Text] [Related]
19. Multiproduct Resin Reuse for Clinical and Commercial Manufacturing-Methodology and Acceptance Criteria.
Sharnez R; Doares S; Manning S; Mehta K; Mahajan E; To A; Daniels W; Glynn J; Dhamane S; Wen X; Wang Y; Gour P; Guenther C; Foley D; Hayes R; Mott A; Prabhu S; Tavalsky D; Hendershot M; Haas D; Hesslein A; Schuelke N; Tjandra H
PDA J Pharm Sci Technol; 2018; 72(6):584-598. PubMed ID: 30030349
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
Mattila J; Curtis S; Webb-Vargas Y; Wilson E; Galperina O; Roush D; Tobler S; Stanley B; Clark M; Weaver J; Pike J; Yu D; Li X; Flicker A; Kindermann J; Schuelke N; Whitcombe R; Bennett L
PDA J Pharm Sci Technol; 2019; 73(5):470-486. PubMed ID: 31101706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
